Collexis' BiomedExperts Rapidly Expanding its User Base

Collexis Holdings, Inc.Collexis Holdings Inc, (OTCBB: CLXS) a leading developer of high definition search and knowledge discovery software, announced that its premier professional scientific social networking site, Biomedexperts.com, has more than 30,000 registered users, enabling researchers across organizations and around the globe to collaborate more efficiently and effectively.

In April Collexis implemented the first phase of their marketing campaign and since that time BiomedExperts' user registrations have skyrocketed from 2,000 to more than 30,000. BiomedExperts.com is a collaborative agreement with Dell Healthcare and Life Sciences. Through this initiative, Dell is providing the hardware and continued marketing support for the site and Collexis is contributing knowledge discovery and text mining applications.

"The success of BiomedExperts.com is a testament to the role innovative technology can play in enabling researchers to collaborate and drive meaningful scientific discoveries," said James Coffin, Ph.D., vice president and general manager, Dell Health Care and Life Sciences. "The possibilities are tremendous when scientists of varying disciplines work together on a similar goal, and in this connected era bringing research communities together through technology can have real and significant impact on scientific discoveries and ultimately patient care."

Pre-populated with over 1.5 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 21 million connections made through the site.

"It's exciting to see how this tool is paving the way for researchers to grow their professional networks and connect with professionals in the scientific research community," said Bill Kirkland, CEO of Collexis Holdings, Inc. "And now, with more than 30,000 registered users, we hope the collaborative opportunities will continue to increase rapidly, furthering our mission to provide scientists and researchers with the tools they need to help advance medical science, thereby improving the greater good."

To learn more about Collexis and how BiomedExperts is improving research capabilities, please visit www.collexis.comwww.collexis.com and www.biomedexperts.com.

Related news articles:

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis’ proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis’ current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Most Popular Now

New App may Help Caregivers of People Ge…

A new study by investigators from Mass General Brigham showed that a new app they created can help improve the quality of life for caregivers of patients undergoing bone marrow...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...